Traditional medicines draft paper
This article was originally published in The Tan Sheet
Executive Summary
The comment period for a draft paper on a new model for regulating traditional medicines in the U.S. has been extended to June 30, the American Herbal Products Association announces March 29. The draft document, "A Proposed Regulatory Model for Traditional Medicines: Guiding Assumptions & Key Components," was released by the Traditional Medicines Congress in November (1"The Tan Sheet" Dec. 5, 2005, In Brief). Despite the 70 comments already received, an extension was requested by several stakeholders, AHPA says. The group also is clarifying certain "areas of confusion": the TM Congress is not suggesting that herbs marketed as supplements under DSHEA be required to be sold as traditional medicines and is not aiming to influence the practice of medicine under any therapeutic discipline...
You may also be interested in...
Traditional medicine
The Traditional Medicines Congress has released a first draft of its detailed model on how to regulate traditional medicines in the U.S., the American Herbal Products Association announces Nov. 29. The 16-page document, "A Proposed Regulatory Model for Traditional Medicines: Guiding Assumptions and Key Components," was published by the nine member organizations of the TM Congress, which formed in spring 2004 to ensure public access to traditional medicinal products. "While some goods that have long been used as traditional medicines fit neatly into [the current legal] framework, the therapeutic uses of these are restricted and many are entirely excluded," AHPA President Michael McGuffin said. "The model proposed here would completely protect the current law while developing a new option that will benefit marketers who want to sell traditional medicines"...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.